Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
AML1/RUNX1 mutations have been reported frequently in myelodysplastic syndrome (MDS) patients, especially those diagnosed with refractory anemia with excess blast (RAEB), RAEB in transformation (RAEBt), or AML following MDS (these categories are defined as MDS/AML). Although AML1 mutations are suspected to play a pivotal role in the development of MDS/AML, acquisition of additional genetic alterations is also necessary. We analyzed gene alterations in MDS/AML patients with AML1 mutations, comparing them to alterations in those without an AML1 mutation. AML1 mutations were significantly associated with -7/7q-, whereas MDS/AML patients without AML1 mutations showed a high frequency of -5/5q- and a complex karyotype. Patients with AML1 mutations showed more mutations of their FLT3, N-RAS, PTPN11, and NF1 genes, resulting in a significantly higher mutation frequency for receptor tyrosine kinase (RTK)-RAS signaling pathways in AML1-mutated MDS/AML patients compared to AML1-wild-type MDS/AML patients (38% versus 6.3%, P < 0.0001). Conversely, p53 mutations were detected only in patients without AML1 mutations. Furthermore, blast cells of the AML1-mutated patients expressing surface c-KIT, and SHP-2 mutants contributed to prolonged and enhanced extracellular signal-regulated kinase activation following stem cell factor stimulation. Our results suggest that MDS/AML arising from AML1/RUNX1 mutations has a significant association with -7/7q- alteration, and frequently involves RTK-RAS signaling pathway activation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Frame-shift mutations in the C-terminus exons of RUNX1 are frequently seen in myelodysplastic syndrome and AML.1”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [1]
In the citing paper
“RUNX1 is frequently inactivated by mutation or translocation in the myeloid cancers myelodysplastic syndrome and acute myeloid leukemia (AML)3 (∼20% of cases)”
From Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy (2014) · cites this paper as [5]
Citations
Cites
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D. L., van der Burgt, I., Brunner, H. G., Bertola, D. R., Crosby, A., Ion, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340847 · Cited by 802
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 778
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Ichikawa, M., Asai, T., Saito, T., Yamamoto, G., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., Chiba, S., Hirai, H., et al. (2004) · Nature Medicine · doi:10.1038/nm997 · Cited by 596
Role of nucleophosmin in embryonic development and tumorigenesis
Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K., & Pandolfi, P. P. (2005) · Nature · doi:10.1038/nature03915 · Cited by 561
Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 455
Cited by
Role of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
“Whether SHP2 mutants can cooperate with AML1 or NPM1 mutants to induce MDS/ AML is of keen interest.”
BackgroundTang, J.-L., Hou, H.-A., Chen, C.-Y., Liu, C.-Y., Chou, W.-C., Tseng, M.-H., Huang, C.-F., Lee, F.-Y., Liu, M.-C., Yao, M., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223784 · Cited by 344
Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 336
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R., Levine, R., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 305
Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C., & Haferlach, T. (2011) · Blood · doi:10.1182/blood-2009-11-255976 · Cited by 265
“Platelet count, 109/L (median, range) 64 (6-1116) 56 (10-301) 71 (6-1116) .”
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Eich, M.-L., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 242
“The EZH2 gene is located at 7q36, thus the RUNX1 alterations can lead to EZH2 loss of function (48, 49).”
BackgroundGenetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 232
Sashida, G., Harada, H., Matsui, H., Oshima, M., Yui, M., Harada, Y., Tanaka, S., Mochizuki-Kashio, M., Wang, C., Saraya, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5177 · Cited by 167
Self-citationChen, C., Lin, L., Tang, J., Ko, B., Tsay, W., Chou, W., Yao, M., Wu, S., Tseng, M., & Tien, H. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06811.x · Cited by 134
“Recently, RUNX1 mutations have been reported in patients with MDS, especially that secondary to atomic-bomb radiation or therapy (Imai et al, 2000; Preudhomme et al, 2000; Harada et al, 2003, 2004; Christiansen et al, 2004; Nakao et al, 2004; Osato, 2004; Steensma et al, 2005; Niimi et al, 2006).”
BackgroundInfluentialDicker, F., Haferlach, C., Kern, W., Haferlach, T., & Schnittger, S. (2007) · Blood · doi:10.1182/blood-2007-02-072595 · Cited by 127
Molecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88
Emberger syndrome—Primary lymphedema with myelodysplasia: Report of seven new cases
Mansour, S., Connell, F., Steward, C. G., Østergaard, P., Brice, G. W., Smithson, S., Lunt, P. W., Jeffery, S., Dokal, I. S., Vulliamy, T., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33445 · Cited by 88
“Familial MDS/AML pedigrees have been reported to demonstrate anticipation (the phenomenon by which increasing severity of a condition or earlier age-of-onset of disease is observed with each passing generation in autosomal dominant disorders) [Owen et al., 2008b].”
BackgroundInfluentialGenetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Pedersen-Bjergaard, J., Andersen, M. T., & Andersen, M. K. (2007) · Hematology · doi:10.1182/asheducation-2007.1.392 · Cited by 99
RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells
Barutcu, A. R., Hong, D., Lajoie, B. R., McCord, R. P., van Wijnen, A. J., Lian, J. B., Stein, J. L., Dekker, J., Imbalzano, A. N., & Stein, G. S. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.08.003 · Cited by 82
NF1 Inactivation in Adult Acute Myelogenous Leukemia
Parkin, B. L., Ouillette, P. D., Wang, Y., Liu, Y., Wright, W., Roulston, D., Purkayastha, A. A., Dressel, A., Karp, J. E., Bockenstedt, P. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2639 · Cited by 79
BERNASCONI, P. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07245.x · Cited by 87
“A recent study has revealed a different clustering of six individual class I mutations along with RUNX1 and TP53 mutations (Pedersen-Bjergaard et al, 2006) (Table V), a finding anticipated by other studies (Niimi et al, 2006).”
ResultAML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
Ding, Y., Harada, Y., Imagawa, J., Kimura, A., & Harada, H. (2009) · Blood · doi:10.1182/blood-2009-06-223982 · Cited by 71
Self-citationMutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies
Bacher, U., Haferlach, C., Schnittger, S., Kohlmann, A., Kern, W., & Haferlach, T. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0920-6 · Cited by 75
“Mutations of the RAS (family of retrovirus-associated DNA sequences) oncogenes were described in 5% of t-MDS cases [12] and in 12% of RUNX1-mutated advanced MDS cases [13].”
BackgroundMolecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations
Harada, Y., & Harada, H. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21769 · Cited by 94
“In AML1-mutated MDS/AML patients, cooperative genetic alterations have been identified (Niimi et al., 2006).”
BackgroundSelf-citationRUNX1 regulates corepressor interactions of PU.1
Hu, Z., Gu, X., Baraoidan, K., Ibanez, V., Sharma, A., Kadkol, S., Munker, R., Ackerman, S., Nucifora, G., & Saunthararajah, Y. (2011) · Blood · doi:10.1182/blood-2010-10-312512 · Cited by 63
“26 Differentiation status was analyzed by: (1) presence of adherent cells by light microscopy, (2) morphologic changes in Giemsastained cytospin preparations, (3) quantitative RT-PCR for stem cell and differentiation gene expression, and (4) flow-cytometry for c-Kit and F4/80 protein expression.”
MethodRUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes
Koh, C. P., Wang, C. Q., Ng, C. E. L., Ito, Y., Araki, M., Tergaonkar, V., Huang, G., & Osato, M. (2013) · Leukemia · doi:10.1038/leu.2013.200 · Cited by 65
Sanada, M., Uike, N., Ohyashiki, K., OZAWA, K., Li-li, W., Hangaishi, A., Kanda, Y., Chiba, S., Kurokawa, M., Omine, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404619 · Cited by 53
Kilbey, A., Blyth, K., Wotton, S., Terry, A., Jenkins, A., Bell, M., Hanlon, L., Cameron, E. R., & Neil, J. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3016 · Cited by 51
Honda, H., Nagamachi, A., & Inaba, T. (2014) · Oncogene · doi:10.1038/onc.2014.196 · Cited by 52
Self-citationOncogene-induced senescence: An essential role for Runx
Terry, A., Cameron, E., Neil, J., & Kilbey, A. (2008) · Cell Cycle · doi:10.4161/cc.6368 · Cited by 46
Yokota, A., Huo, L., Lan, F., Wu, J., & Huang, G. (2020) · PubMed Central · doi:10.14348/molcells.2019.0252 · Cited by 67
“Mutated RUNX1 was also frequently associated with additional aberrations, such as -7/7q-, -5/5q-, and ASXL1, EZH2, KRAS, NRAS, SUZ12, CBL, FLT3-ITD, and TET2 mutations, in this group (Chao et al., 2017; Skokowa et al., 2014).”
BackgroundInfluentialRipperger, T., Steinemann, D., Göhring, G., Finke, J., Niemeyer, C. M., Strahm, B., & Schlegelberger, B. (2009) · Leukemia · doi:10.1038/leu.2009.87 · Cited by 45
Gu, X., Hu, Z., Ebrahem, Q., Crabb, J. S., Mahfouz, R. Z., Radivoyevitch, T., Crabb, J. W., & Saunthararajah, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562447 · Cited by 42
Advancements in the molecular pathogenesis of myelodysplastic syndrome
Epling‐Burnette, P. K., & List, A. F. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257ac7 · Cited by 45
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
Lee, P., Yim, R., Yung, Y., Chu, H.-T., Yip, P.-K., & Gill, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910232 · Cited by 43
Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes
Aoyagi, Y., Hayashi, Y., Harada, Y., Choi, K., Matsunuma, N., Sadato, D., Maemoto, Y., Ito, A., Yanagi, S., Starczynowski, D. T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0032 · Cited by 37
Self-citationHarada, Y., Inoue, D., Ding, Y., Imagawa, J., Doki, N., Matsui, H., Yahata, T., Matsushita, H., Ando, K., Sashida, G., et al. (2013) · Blood · doi:10.1182/blood-2012-06-434423 · Cited by 34
Self-citationSlovak, M. L., Smith, D. D., Bedell, V., Hsu, Y., O'Donnell, M. R., Forman, S. J., Gaal, K. K., McDaniel, L. D., Schultz, R. A., Ballif, B. C., et al. (2010) · Molecular Cytogenetics · doi:10.1186/1755-8166-3-23 · Cited by 29
“and without RUNX1 alterations have been reported in -7/7q- alterations in AML arising from MDS and chronic myelomonocytic leukemia with myelodysplastic features [37-39].”
BackgroundZharlyganova, D., Harada, H., Harada, Y., Shinkarev, S. M., Zhumadilov, Z. S., Zhunusova, A., TCHAIZHUNUSOVA, N. J., Apsalikov, K., Kemaykin, V., Zhumadilov, К., et al. (2008) · Journal of Radiation Research · doi:10.1269/jrr.08040 · Cited by 32
Self-citationPrall, W. C., Czibere, A. G., Grall, F. T., Spentzos, D., Steidl, U. G., Giagounidis, A. A. N., Kuendgen, A., Otu, H. H., Rong, A., Libermann, T. A., et al. (2009) · International Journal of Hematology · doi:10.1007/s12185-008-0242-9 · Cited by 28
The Genetic Basis of Myelodysplastic Syndromes
Bejar, R. L., & Ebert, B. L. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.001 · Cited by 29
Christiansen, D. H., Desta, F., Andersen, M. K., & Pedersen-Bjergaard, J. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20426 · Cited by 26
“Acquired, activating mutations of PTPN11 were subsequently detected as the most frequent molecular lesion in patients with juvenile myelomonocytic leukemia (JMML) but without Noonan syn- drome (Tartaglia et al., 2003; Kratz et al., 2005), and sporadically also in patients with de novo MDS, AML and ALL (Tartaglia et al…”
BackgroundInfluentialMyelodysplastic Syndromes (MDS)
Pleyer, L., Neureiter, D., Faber, V., & Greil, R. (2010) · Springer eBooks · doi:10.1007/978-3-211-79892-8_6 · Cited by 25
Imagawa, J., Harada, Y., Shimomura, T., Tanaka, H., Okikawa, Y., Hyodo, H., Kimura, A., & Harada, H. (2010) · Blood · doi:10.1182/blood-2010-06-289389 · Cited by 25
Self-citationEpling‐Burnette, P. K., & Loughran, T. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003801076 · Cited by 23
“Mutations of RAS genes, or activation of RAS in the absence of mutations, occurs in high frequency in MDS and AML, suggesting that targeted disruption of this important signaling molecule may be used therapeutically [8,9,14-16].”
BackgroundPossible involvement of RasGRP4 in leukemogenesis
Watanabe‐Okochi, N., Oki, T., Komeno, Y., Kato, N., Yuji, K., Ono, R., Harada, Y., Harada, H., Hayashi, Y., Nakajima, H., et al. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0299-0 · Cited by 22
Self-citationToya, T., Yoshimi, A., Morioka, T., Arai, S., Ichikawa, M., Usuki, K., & Kurokawa, M. (2013) · Platelets · doi:10.3109/09537104.2013.818636 · Cited by 19
“Harada et al. reported that mutation frequency of receptor tyrosine kinase (RTK)-RAS signaling pathway is significantly higher in sporadic RUNX1-mutated MDS/AML than in RUNX1-wild type MDS/AML [13].”
Quesada, A. E., Bravo, G. M., Luthra, R., Patel, K. P., Sasaki, K., Bueso-Ramos, C., Khoury, J. D., Routbort, M. J., Bassett, R. L., Hidalgo‐Lόpez, J. E., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0531-2 · Cited by 20
AML1/RUNX1 gene point mutations in childhood myeloid malignancies
Migas, A. A., Savva, N. N., Mishkova, V., & Aleinikova, O. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22980 · Cited by 17
“According to published literature [2,3,5,7] and our observations we may conclude that such a combination of genetic anomalies can be considered a feature of an induced neoplasm.”
BackgroundGenome wide molecular analysis of minimally differentiated acute myeloid leukemia
Silva, F. P. G., Almeida, M. I., Morolli, B., Brouwer-Mandema, G., Wessels, H. M. C., Vossen, R. H. A. M., Vrieling, H., Marijt, E. W. A., Valk, P. J. M., Kluin‐Nelemans, H. C., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.009324 · Cited by 16
“Contrary to previous findings, mutation of RAS pathway-related genes did not correlate with RUNX1 mutation.(14,44) We also did not find a positive association between -7/del(7q) and RUNX1 mutation or a negative one between del(5q) and RUNX1 mutation as previously reported in myelodysplastic syndrome,(44) although a si…”
ResultUpdate on genetic and molecular markers associated with myelodysplastic syndromes
Valent, P., & Wieser, R. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902756107 · Cited by 13
“Interestingly, N-RAS mutations in MDS are often found in association with RUNX1 point mutations and other somatic mutations [52].”
BackgroundMitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies
Czegle, I., Gray, A. L., Wang, M., Liu, Y., Wang, J., & Wappler-Guzzetta, E. A. (2021) · Life · doi:10.3390/life11121351 · Cited by 12
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH)
Munker, R., Nordberg, M. L., Veillon, D. M., Williams, B. J., Roggero, A. L., Kern, W., Dicker, F., & Haferlach, T. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.04.008 · Cited by 11
Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children
Clark, J., Berman, J. N., & Look, A. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00011-x · Cited by 10
The Role of RUNX1 in NF1-Related Tumors and Blood Disorders.
Na, Y., Huang, G., & Wu, J. (2020) · PubMed Central · doi:10.14348/molcells.2019.0295 · Cited by 8
“RUNX1 mutations have a significant association with -7/7q- alteration, and frequently involve receptor tyrosine kinase (RTK)-RAS signaling pathway activation (Niimi et al., 2006).”
BackgroundCytogenetic Diagnosis of Myelodysplastic Syndromes
Olney, H. J., & Beau, M. M. L. (2006) · Springer eBooks · doi:10.1007/3-540-30794-x_6 · Cited by 6
Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia
Hou, H., Chou, W., & Tie, H.-F. (2011) · InTech eBooks · doi:10.5772/26421 · Cited by 5
Huang, H., Li, B.-X., Qin, T. J., Xu, Z., Hu, N., Pan, L. J., Qu, S. Q., Liu, D., Zhang, Y. D., & Xiao, Z. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.09.004 · Cited by 4
“[24] Niimi H, Harada H, Harada Y, et al.”
BackgroundBraekeleer, E. D., Douet‐Guilbert, N., Basinko, A., Bris, M. L., Morel, F., Berthou, C., Férec, C., & Braekeleer, M. D. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0937-x · Cited by 4
“RUNX1 mutations were found to be significantly associated with monosomy 7 or partial deletion of the long arm of chromosome seven in studies of MDS/AML patients [5, 7].”
BackgroundInfluentialFeng, Y., Liang, H., Luo, X., Zhu, Y., Liu, B., & Han, M. (2023) · Hematology · doi:10.1080/16078454.2023.2220222 · Cited by 4
“RUNX1 mutations are often accompanied by a hyperactivated RTK-Ras signaling pathway in patients with MDS [32].”
BackgroundКлінічне значення генетичних мутацій при гострій мієлоїдній лейкемії
Goryainova, N. V. (2014) · Likarska sprava · doi:10.31640/ls-2014-12-02 · Cited by 1
Cytogenetic Diagnosis of Myelodysplastic Syndromes
Olney, H. J., & Beau, M. M. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-36229-3_3 · Cited by 2
Deciphering a Kit-Shp2-Kit Axis in Regulation of Adult Hematopoietic Stem and Progenitor Cells
Zhu, H. (2011) · eScholarship (California Digital Library)
Kimura, A. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.2612
Self-citation[Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
Harada, H. (2007) · PubMed · doi:10.11406/rinketsu.48.541
Self-citationBarutcu, A. R. (2016) · eScholarship@UMassChan · doi:10.13028/m2t01z
“In particular, RUNX1 is involved in the RAS, ERK, TGFβ and WNT signaling pathways in a variety of cellular contexts including cancer [281-284].”
BackgroundHeim, S., & Mitelman, F. (2010) · Wiley eBooks · doi:10.1002/9781118010136.ch6
Data from NF1 Inactivation in Adult Acute Myelogenous Leukemia
Parkin, B. L., Ouillette, P. D., Wang, Y., Liu, Y., Wright, W., Roulston, D., Purkayastha, A. A., Dressel, A., Karp, J. E., Bockenstedt, P. L., et al. (2023) · doi:10.1158/1078-0432.c.6519537
Data from NF1 Inactivation in Adult Acute Myelogenous Leukemia
Parkin, B. L., Ouillette, P. D., Wang, Y., Liu, Y., Wright, W., Roulston, D., Purkayastha, A. A., Dressel, A., Karp, J. E., Bockenstedt, P. L., et al. (2023) · doi:10.1158/1078-0432.c.6519537.v1
Aoyagi, Y., Hayashi, Y., Harada, Y., Choi, K., Matsunuma, N., Sadato, D., Maemoto, Y., Ito, A., Yanagi, S., Starczynowski, D. T., et al. (2023) · doi:10.1158/2159-8290.c.6549430.v1
Self-citationIdentification of multi-target phytochemicals against FLT3, KIT and RUNX1 in acute myeloid leukemia
Aloufi, B. H., & Badraoui, R. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03623
Subsampled ChIPseq FASTQs from GSE75070
Orofino, J. (2024) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10601900
Metadata
- Authors
- Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A.
- Affiliations
- Hiroshima University (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- Corresponding author
- Harada, H
- Venue
- Leukemia
- Published
- 2006-02-09
- Volume
- 20
- Issue
- 4
- Pages
- 635-644
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2107874457
- Cited by
- 69
- References
- 54
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 4 · 2021: 3 · 2020: 5 · 2018: 1 · 2017: 1 · 2016: 2 · 2014: 4 · 2013: 4
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- myelodysplastic syndrome, Ras signaling, FLT3 mutation, NRAS mutation, PTPN11 mutation, NF1 mutation, TP53 mutation, CD117, SHP2, ERK activation, stem cell factor, MDS/AML, complex karyotype
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Chromosome Aberrations, DNA Mutational Analysis, Epidermal Growth Factor, Female, Humans, Ligands, Male, Middle Aged, Myelodysplastic Syndromes, Genes, ras, Sensitivity and Specificity, Tumor Cells, Cultured, Signal Transduction, Leukemia, Myeloid, Acute, Granulocyte-Macrophage Colony-Stimulating Factor, Protein Tyrosine Phosphatases, Point Mutation, Cytogenetic Analysis, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Core Binding Factor Alpha 2 Subunit, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.